Advance in human papillomavirus major capsid protein L1-based vaccines

VernacularTitle: 基于人乳头瘤病毒主要衣壳蛋白L1的疫苗研究进展
Author: Chunting HUA ¹ ; Siyuan SUN ¹ ; Hao CHENG ¹ ; Rui HAN ¹
Author Information

1. Department of Dermatology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China
Publication Type:Review
Keywords: Human papillomavirus; Major capsid protein L1; Virus like particle; HPV vaccine
From: Chinese Journal of Microbiology and Immunology 2019;39(10):788-793
CountryChina
Language:Chinese
Abstract: L1 is the major capsid protein of human papillomavirus (HPV) encoded by late gene 1. Based on the fact that L1 can self-assemble into virus like particle (VLP) with good immunogenicity, it has aroused wide concern in studying the pathogenesis of and vaccines against HPV. Nevertheless, there are a few limitations of present L1-based HPV vaccines. For instance, low expression of the protein and the complexity of purification result in the relatively low yield of vaccines. Type-specific antibody induced by L1 also results in the unsatisfactory cross-protection rate. Furthermore, there is no reported therapeutic effect against HPV-related diseases because of its undefined role in virus eliminating. This review focused on the structure, immunogenicity and role in immune response of L1 and the development of and latest progress in HPV vaccines.